

1  
2 **Glycomacropeptide from Camel Milk Inhibits the Adhesion of Enterotoxigenic *Escherichia***  
3 ***coli* K88to Porcine Cells**

4 Rami M. Althnaibat<sup>1)</sup>, Mandy Koch<sup>2)</sup>, Heather L. Bruce<sup>1)</sup>, Daniel Wefers<sup>2)</sup>, Michael G. Gänzle<sup>1\*)</sup>

5 1) University of Alberta, Dept. of Agricultural, Food and Nutritional Science, Edmonton, AB,  
6 Canada.

7 <sup>2)</sup> Martin Luther University Halle-Wittenberg, Institute of Chemistry, Institute of Chemistry, Food  
8 Chemistry – Functional Food, Halle (Saale), Germany

9 <sup>\*)</sup> Corresponding author footnote

10 Michael Gänzle,

11 University of Alberta, Dept. of Agricultural, Food and Nutritional Science

12 4-10 Ag/For Centre

13 Edmonton, AB

14 Canada, T6G 2P5

15 mail; [mgaenzle@ualberta.ca](mailto:mgaenzle@ualberta.ca)

16

17

18 **Abstract**

19 Enterotoxigenic *Escherichia coli* (ETEC) are a major cause of childhood diarrhea and of diarrhea  
20 in piglets and calves. This study compared the anti-adhesive activities against ETEC of  
21 glycomacropeptide (GMP) from Bactrian camels and dromedaries to bovine GMP. GMP was  
22 purified by ion exchange chromatography and ultra-filtration. The monosaccharide content of  
23 GMP from Bactrian camels and dromedaries was about twice as high when compared to bovine  
24 GMP. Glycans from camels included fucose and N-acetylglucosamine, which were absent in  
25 bovine GMP. GMP from both camel species prevented ETEC adhesion to porcine blood cells at a  
26 concentration of 0.24 g L<sup>-1</sup> to 0.28 g L<sup>-1</sup> respectively, a concentration that is about 20-fold lower  
27 when compared to bovine GMP. This increased activity likely relates to the increased  
28 glycosylation and the density of glycan spacing, and / or to differences in the glycan composition.

29 **KEYWORDS:** Bactrian camel, dromedary, glycomacropeptide, enterotoxigenic *Escherichia coli*,  
30 antiadhesive activity, glycosylation, glycan density spacing, glycan structure.

31

## 32 **Introduction**

33 Enterotoxigenic *Escherichia coli* (ETEC) are a major cause of childhood diarrhea in developing  
34 countries, and cause traveler's diarrhea. ETEC also cause watery diarrhea in newborn and post-  
35 weaning piglets and calves (DuPont, 1995; Qadri, Svennerholm, Faruque, & Sack, 2005). ETEC  
36 produce two enterotoxins, the heat stable enterotoxin (ST) and the heat labile enterotoxin (LT).  
37 ETEC adhere to the small intestinal epithelial cells and to the mucosal tissue through glycoprotein  
38 receptors of the host cells using specific fimbriae. Colonization of the microvilli and the production  
39 of enterotoxins lead to electrolyte imbalance and water loss (Chen, Woodward, Zijlstra, & Gänzle,  
40 2014; Nagy & Fekete, 2005). *E. coli* expressing K88 fimbriae are among the most prevalent strains  
41 of ETEC that cause diarrhea in swine (Chen et al., 2014; Hermes, Manzanilla, Martín-Orúe, Pérez,  
42 & Klasing, 2011).

43 The mortality rate in farm animals due to bacterial infections is increasing especially at the  
44 weaning stage (Nagy & Fekete, 2005). The use of antibiotics to control ETEC in pig production  
45 increases costs, supports the emergence of antibiotics resistant pathogens in animals as well as the  
46 transmission of antibiotic resistance to human pathogens (Docic & Bilkei, 2003). These problems  
47 led to search for alternative approaches to control ETEC (Docic & Bilkei, 2003). Anti-adhesive  
48 biomolecules that act as glycan receptor analogues are a promising alternative to antibiotics.  
49 Glycan receptors bind to glycolipids or glycoproteins on the surface of host tissues and thus  
50 mediate adhesion of pathogens and toxins including the adherence of ETEC fimbriae to the  
51 epithelial cells (Kulkarni, Weiss, & Iyer, 2010; Shoaf-Sweeney & Hutkins, 2008). Glycan receptor  
52 analogues bind to these glycan receptors and thus inhibit the initial stages of infection and bacterial  
53 colonization (Kulkarni et al., 2010; Shoaf-Sweeney & Hutkins, 2008). Anti-adhesive agents do

54 not have bactericidal or bacteriostatic activity and therefore do not result in development of  
55 antimicrobial resistance (Krachler & Orth, 2013; Shoaf-Sweeney & Hutkins, 2008).

56 Anti-adhesive agents that inhibit the adhesion of ETEC include human milk oligosaccharides  
57 (HMOs) as well as oligosaccharides in bovine colostrum which prevent ETEC adhesion in calves  
58 (Fong, Ma, & McJarrow, 2011). Major HMOs are composed of fucose, galactose, glucose, N-  
59 acetyl-glucosamine, and N-acetyl-neuraminic acid or sialic acid (Bode et al., 2016). However,  
60 human milk is not commercially available and HMO analogs that are purified from bovine  
61 colostrum or produced with microbial cell factories are relatively expensive (Ackerman, Craft, &  
62 Townsend, 2017; Bode et al., 2016). Alternative oligosaccharides or glycopeptides known to  
63 inhibit ETEC adhesion include glycans formed by *Limosilactobacillus reuteri*, glycopeptides  
64 obtained from ovomucin hydrolysis, and galactosylated chitosan oligosaccharides (Sun, Gänzle,  
65 & Wu, 2017; Wang, Gänzle, & Schwab, 2010; Yan, Hu, Simpson, & Gänzle, 2017). Ovomucin-  
66 derived glycopeptides prevent adhesion of porcine ETEC K88 fimbriae at minimum inhibitory  
67 concentration (MIC) of 2.5 g L<sup>-1</sup> while β-galactosylated chitosan-oligosaccharides inhibit ETEC  
68 K88 adhesion at MIC of 0.22 g L<sup>-1</sup> (Sun et al., 2017; Yan et al., 2017).

69 Bovine glycomacropeptide (GMP) constitutes about 15-20 % of the total whey protein and  
70 represents the C-terminus of κ-casein obtained by specific hydrolysis of κ-casein with rennet. GMP  
71 contains a high portion of sialic acid, which constitutes 7-9 % of its the total weight (Li & Mine,  
72 2004; Nakano, Ozimek, & Betti, 2018). Bovine GMP also blocks the adhesion of diverse enteric  
73 pathogens to the intestinal mucosa including enterohemorrhagic *E. coli* (EHEC) O157 (Nakajima  
74 et al., 2005) and ETEC K88 adhesion in swine (Hermes et al., 2013). Bovine GMP prevents  
75 adhesion of porcine ETEC K88 fimbriae at MIC of 2.5 g L<sup>-1</sup> (Hermes et al., 2013).

76 In North Africa and in the Middle East, the production of camel milk cheese has increased; this  
77 increase in camel milk cheese production also increased the amount of whey as a by-product (El-  
78 Agamy, 2009). Comparable to other domestic animals, ETEC causes diarrhea in camel calves (Al-  
79 Ruwaili, Khalil, & Selim, 2012). Camel milk is not as well studied as bovine milk and the chemical  
80 composition and the biological activities of camel GMP are not described. Therefore, this study  
81 aimed to purify GMP from camel milk, to characterize its glycan composition, and to assess its  
82 activity in preventing adhesion of ETEC K88 adhesion to porcine erythrocytes.

### 83 **Materials and methods**

84 **Purification of GMP.** Bovine GMP was purchased from Davisco Foods International (Eden  
85 Prairie, MN, USA). GMP from Bactian camels or dromedaries was purified from cheese whey that  
86 was prepared by treatment of reconstituted lyophilized milk from Bactrian camels (Inner Mongolia  
87 Agricultural University, China) or of reconstituted spray dried milk from dromedary camels (Al  
88 Ain Farms, Al Ain, UAE) with camel chymosin (Chr. Hansen, Bayswater, Australia), followed by  
89 separation of whey by centrifugation (Figure 1). GMP was purified as previously described with  
90 some modifications (Nakano et al., 2018), as illustrated in Figure 1. Briefly, about 25 mL whey  
91 with a pH of 6.2 was ultra-filtrated, dialyzed with 5 kDa membranes and then incubated in boiling  
92 water for 10-12 min to denature whey proteins. After cooling to room temperature (22 °C),  
93 precipitated protein was removed by centrifugation at 5, 000 ×g for 40 min at 20 °C. The pH of  
94 the supernatant was adjusted with 2M HCl to 4.3, the pI of camel milk casein, and precipitates  
95 were removed by centrifugation. The pH of the supernatant was adjusted to pH 3.0 with 2 M HCl  
96 and the solution was loaded on a 1.5 cm × 20 cm column of diethylaminoethyl (DEAE)-Sephadex  
97 A-25 (GE Healthcare, Chicago, IL). GMP was eluted with a linear gradient of 0 to 1 M NaCl.  
98 GMP eluting from the column was detected by measuring the absorbance at 549 nm after

99 derivatization with thiobarbituric acid (Warren, 1959). Camel milk oligosaccharides were prepared  
100 with the same protocol from acidic whey that was not treated with chymosin.

101 **Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).** SDS-PAGE was  
102 carried out with 4-20 % acrylamide ready to use gels (Mini-PROTEAN TGX Precast Protein Gels,  
103 Bio-Rad Laboratories, Hercules, CA, USA). GMP was dissolved in distilled water containing  
104 2.5 % (v/v) mercaptoethanol to a concentration of 5 g L<sup>-1</sup>, diluted 1 : 4 (v/v) with SDS loading  
105 buffer, heated at 90°C for 5 min, and loaded on the gel. Proteins were separated for 50 min at  
106 150 V and protein bands were stained with Coomassie Blue. Thermo Scientific PageRuler™  
107 Prestained Protein Ladder (10-250 kDa), and Spectra™ Multicolor Low Range Protein Ladder  
108 (1.7- 40kDa) (Fisher Scientific) were used as molecular markers.

109 **Reverse phase high performance liquid chromatography coupled to mass spectrometry**  
110 **(LC-MS).** LC-MS analyses of GMP were by the Mass Spectrometry Laboratory of the Department  
111 of Chemistry at the University of Alberta. LC-MS was performed with an Agilent 1200 SL HPLC  
112 System and a Phenomenex Aeris 3.6 µm, WIDEPORE XB-C8, 200 Å, 2.1 x 50 mm guard column.  
113 The column was eluted at 0.5 ml min<sup>-1</sup> and 40 °C with 0.1% (v/v) formic acid in water (A) and  
114 0.1% formic acid in acetonitrile (B) with the following linear gradient: 0 min, 5 % B; 0.5 min, 5%  
115 B; 5.5 min, 60 % B; 7 min, 98 % B, followed by washing for 2.8 min and re-equilibration. Mass  
116 spectra were acquired in positive mode of ionization using an Agilent 6220 Accurate-Mass TOF  
117 LC/MS system (Santa Clara, CA, USA) equipped with a dual sprayer electrospray ionization  
118 source. Mass correction was performed for every individual spectrum using peaks at m/z 121.0509  
119 and 922.0098 from the reference solution. Mass spectrometric conditions were drying gas 10  
120 L min<sup>-1</sup> at 325 °C, nebulizer 20 psi, mass range 100-3000 Da, acquisition rate of ~1.03 spectra/sec,  
121 fragmentor 225 V, skimmer 65 V, capillary 4000 V, instrument state 4 GHz High Resolution. Data

122 analysis was performed using the Agilent Mass Hunter Qualitative Analysis software package  
123 version B.03.01 SP3.

124 **Determination of glycan composition.** To analyze monosaccharide content and distribution of  
125 GMPs from cows, Bactrian camels, and dromedaries, 20  $\mu\text{L}$  of a 5  $\text{g L}^{-1}$  solution of GMP were  
126 hydrolyzed by using 2 M trifluoroacetic acid (TFA). Briefly, samples were first dried with an  
127 evaporator (Eppendorf Concentrator, Hamburg, Germany) at 45  $^{\circ}\text{C}$ , followed by addition of 1 mL  
128 of 2 M TFA and incubation 1 h at 121  $^{\circ}\text{C}$ . For the determination of N-acetylneuraminic acid, a  
129 reaction temperature of 70  $^{\circ}\text{C}$  was used for hydrolysis with 2 M TFA. After incubation, samples  
130 were evaporated and subsequently washed twice with 200  $\mu\text{L}$  ethanol. The dried hydrolysates were  
131 finally dissolved in 200  $\mu\text{L}$  of ultrapure water and analyzed by high performance anion exchange  
132 chromatography with pulsed amperometric detection (HPAEC-PAD) on an ICS6000 system  
133 (Thermo Fisher Scientific, Waltham, MA.) equipped with a Dionex<sup>TM</sup> CarboPac<sup>TM</sup> PA20 column  
134 (150 mm x 3 mm i.d., 6.5  $\mu\text{m}$  particle size, Thermo Fisher Scientific, Waltham, MA.). The eluents  
135 used for the gradient were A) ultrapure water, B) 10 mM sodium hydroxide, C) 200 mM sodium  
136 hydroxide and D) 200 mM sodium hydroxide with 200 mM sodium acetate. The flow rate was of  
137 0.4  $\text{mL min}^{-1}$  at 30  $^{\circ}\text{C}$ . Before every run, the column was rinsed with 100 % B for 10 min and then  
138 conditioned with 30 % A and 70 % B for an additional 10 min. After injection, samples were eluted  
139 with the following gradient: 0 - 27.5 min isocratic with 30 % A and 70 % B; 27.5-35 min linear to  
140 100 % C; 35 - 45 min linear to 100 % D, 45 - 50 min isocratic 100 % D, 50 - 60 min isocratic with  
141 100% C to remove the acetate from the column.

142 **Bacterial strains and growth conditions.** A porcine ETEC expressing K88 fimbriae, *E. coli* ECL  
143 13795, was used to determine the anti-adhesion activity. ETEC K88 was cultivated on Minca agar  
144 aerobically at 37  $^{\circ}\text{C}$  for 6 - 8 h. Cells were washed from the plates with 3 mL of phosphate buffered

145 saline (PBS, 137 mM NaCl; 2.7 mM KCl; 10 mM Na<sub>2</sub>HPO<sub>4</sub>; 1.8 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.2). The cell  
146 density of the suspension was determined by measuring the optical density (OD) at 600 nm and  
147 adjusted to approximately 10<sup>9</sup> CFU mL<sup>-1</sup> as described (Yan et al., 2017).

148 **Hemagglutination assay to detect the impact of GMP on ETEC K88 adhesion to piglet**  
149 **erythrocytes.** Hemagglutination was performed in V-bottom 96-well polystyrene microtiter plates  
150 (Corning) as previously described (Yan et al., 2017). Briefly, porcine whole blood cells  
151 (Innovative Research Inc., USA) were washed three times in PBS and erythrocytes were  
152 resuspended in PBS to a final density 5 % (v/v). ETEC K88 suspension (25 µL with about  
153 10<sup>9</sup> CFU mL<sup>-1</sup>) was added to the first-column of the microtitre plates and diluted horizontally in  
154 ten two-fold serial dilutions. Samples or controls were dissolved at 10 g L<sup>-1</sup> and diluted in 8 serial  
155 twofold dilutions in PBS. Different concentrations of the same sample or control (25 µL each)  
156 were added to the same column of the microtitre plate. The plates were incubated at room  
157 temperature (23 °C) for 5 min prior to addition of 25 µL of erythrocyte suspension. Plates were  
158 incubated overnight (16 h) at 4 °C before visual scoring of agglutination of erythrocytes as  
159 described (Wang et al., 2010). Anti-adhesive activity was recorded if the sample or control solution  
160 increased the number of ETEC K88 cells that agglutinate erythrocytes at least four-fold. The  
161 lowest concentration of GMP with anti-adhesive activity was recorded as minimum anti-adhesive  
162 concentration (MAC). Addition of PBS, bovine serum albumin (BSA), lactose, and  
163 oligosaccharides from acidic whey served as negative controls. Bovine GMP was used as a positive  
164 control.

165 **Enzyme-Linked Immunosorbent Assay (ELISA) to test the ability of GMP to prevent ETEC**  
166 **K88 adhesion to porcine erythrocytes.** The ELISA assay was conducted in 96-well high bind



167 microtiter plates (Corning) as previously described (Yan et al., 2017) with minor modifications to  
168 confirm the impact of GMP on ETEC K88 adhesion to piglet erythrocytes.

169 Briefly, 100  $\mu\text{L}$  of 5 % porcine erythrocytes were added to coat high bind 96-well plate for 16 h,  
170 and plates were then blocked by addition of 200  $\mu\text{L}$  of 3 % BSA, followed by incubation for 60  
171 min at 4 °C. GMP and controls were dissolved in PBS to 10 g L<sup>-1</sup> and diluted in PBS in 8 serial  
172 twofold dilutions. ETEC suspensions were mixed with GMP or control solutions 1:1 (v/v) before  
173 100  $\mu\text{L}$  of the mixtures were added to the plate and incubated for 60 min at 4 °C. Then 100  $\mu\text{L}$  of  
174 1:2000 diluted mouse anti *E. coli* K88A antibody (Bio-Rad Laboratories, Hercules, CA, USA) was  
175 added and incubated at 4 °C for 60 min. Then 100  $\mu\text{L}$  of 1:1000 diluted goat antimouse IgG (H+L)  
176 secondary antibody (Invitrogen, Fisher Scientific, CA, USA) was added, followed by incubation  
177 for 60 min at 4 °C. TMB substrate (50  $\mu\text{L}$ ) was then added to each well. The reaction was stopped  
178 after 30 min by adding 50  $\mu\text{L}$  of 2M sulfuric acid, and the absorbance at 450 nm was determined  
179 with a Varioscan Flash Microplate reader (Thermo Scientific, CA, USA). Between each step of  
180 the above protocol, three washing steps with 200  $\mu\text{L}$  of PBS were performed. Erythrocytes without  
181 ETEC suspension, erythrocytes with ETEC suspension but without samples, and ETEC suspension  
182 without erythrocytes were used as controls in addition to the same negative and positive controls  
183 that were also used in the hemagglutination assay.

184 **Deglycosylation of GMP.** To remove the glycans (free oligosaccharides) from GMP, the  
185 *O*-glycosidase kit (P0733S, 40,000,000-units mL<sup>-1</sup>, New England BioLabs, ON, Canada) was used  
186 with and without neuraminidase (sialidase) (11585886001, 5 U, Sigma, Mannheim, Germany).  
187 Briefly, 20  $\mu\text{g}$  of GMP was mixed with 1  $\mu\text{L}$  of 10X glycoprotein denaturing buffer in 10  $\mu\text{L}$  H<sub>2</sub>O.  
188 After denaturation of GMP denaturation at 100 °C for 10 min, 2  $\mu\text{L}$  of 10X GlycoBuffer (2), 2  $\mu\text{L}$   
189 of 10 % NP40, 2  $\mu\text{L}$  of sialidase, and 3  $\mu\text{L}$  of *O*-glycosidase were added. The mixture was

190 incubated for 3 h at 37 °C. The enzyme kit that was used for protein deglycosylation hydrolyses  
191 O-glycosidic bonds of the disaccharide Gal-β-1-3GalNAc as well as larger oligosaccharides (Ishii-  
192 Karakasa, Iwase, Hotta, Tanaka, & Omura, 1992).

### 193 **Statistical Analysis.**

194 Bioassays were performed in triplicate biological repeats with three technical repeats each and  
195 results are presented as means ± standard deviation. Statistical differences were determined with  
196 one way ANOVA and Least Significant Difference (LSD) post hoc analysis in Minitab 19.  
197 Differences between values were significant with an error probability of 5% ( $P < 0.05$ ).

### 198 **Results**

199 **GMP Purification.** GMP from Bactrian camels and dromedaries were purified with a protocol  
200 that was developed for bovine GMP and employs rennet- and heat induced precipitation of casein  
201 and whey proteins, respectively, and ultra-filtration. Negatively charged GMP was then separated  
202 on an anion exchange column (Fig. 2 A, B). GMP is glycosylated and phosphorylated (Fig. 3).  
203 The predicted molecular weights (Mw) (<https://peptidenexus.com/peptide>) of non-glycosylated  
204 GMPs from Bactrian camel and cows were 6.774 kDa and 6.707 kDa respectively. The mass  
205 spectra obtained by ESI-LC-MS included the predicted ion species of non-glycosylated GMP for  
206 Bactrian camels and cows at 6.777 kDa and 6.787 kDa respectively; additional peaks were  
207 observed that likely represent the peptides with different levels of glycosylation and  
208 phosphorylation (Fig. S1). The purity of purified Bactrian camel GMP, dromedary GMP, and  
209 bovine GMP were assessed by SDS-PAGE (Figure 4). The pattern of all GMPs samples presented  
210 visible regular thin band located at about ~14 kDa, corresponding to the dimeric GMP form  
211 composed of 2 GMP monomers. The separation of bovine GMP and GMP from dromedary milk  
212 produced additional bands with an apparent Mw of 14 – 30 kDa.

213 **Composition of the glycans in GMP from cattle, Bactrian camels, and dromedaries.** To  
214 determine the glycan composition of the GMPs, glycans were hydrolyzed with 2 M TFA, and the  
215 concentration of resulted monosaccharides was determined (Table 1). Hydrolysis of glycans with  
216 2 M TFA not only hydrolyses the glycosidic bonds but also partially or completely deacetylates  
217 N-acetylglucosamine and N-acetylgalactosamine; these are therefore detected as the  
218 corresponding amino sugars. The amount of total monosaccharides from bovine GMP was less  
219 than 50 % of the amount of monosaccharides from Bactrian camel and dromedary GMPs. Fucose  
220 and glucosamine were detected in GMP from Bactrian camels and dromedaries but absent (fucose)  
221 or only present in a low concentration (glucosamine) in bovine GMP. Galacturonic acid and  
222 glucuronic acid were detected in GMP from Bactrian camels only (Table 1). The monosaccharide  
223 composition after hydrolysis of GMP from Bactrian camels and dromedaries also differed  
224 qualitatively and quantitatively, e.g. GMP from dromedaries contained more glucose than GMP  
225 from Bactrian camels.

226 **Impact of GMP on ETEC K88 adhesion to porcine erythrocytes.** The hemagglutination assay  
227 was performed for GMP from Bactrian camel and dromedary milk, using bovine GMP,  
228 oligosaccharides from camel acidic whey, bovine serum albumin (BSA) and lactose served as  
229 controls. The strongest anti-adhesive activities against ETEC K88 were observed for Bactrian  
230 camel GMP (Table 2). BSA and lactose had no anti-adhesive activities against ETEC K88.  
231 However, oligosaccharides from Bactrian camel acidic whey that was prepared without chymosin  
232 treatment, had a lower minimum anti-adhesive concentration than the positive control (Table 2).

233 ELISA was used to confirm the activity of GMP from milk of Bactrian camels and controls in  
234 preventing ETEC K88 adhesion to porcine erythrocytes. Comparable to the hemagglutination  
235 assay, the highest anti-adhesive activity was observed for Bactrian GMP, followed by

236 oligosaccharides from Bactrian camel acidic whey, bovine GMP, lactose, and BSA respectively  
237 (Figure 5). At a concentration of 10 g L<sup>-1</sup>, Bactrian camel GMP reduced ETEC adhesion by about  
238 75 %: at 0.125 g L<sup>-1</sup>, Bactrian camel GMP still significantly reduced ETEC adhesion (Figure 5).  
239 The results from both assays, hemagglutination and ELISA, thus demonstrate that GMP from  
240 Bactrian camels and dromedaries as well as oligosaccharides from Bactrian camel acidic whey had  
241 higher anti-adhesive activities when compared to bovine GMP.

242 **Deglycosylation of GMP.** To determine whether the effect on ETEC adhesion requires that  
243 oligosaccharides are bound to the peptide backbone, the activity of GMPs was compared to the  
244 activity remaining after enzymatic deglycosylation with sialidase and *O*-glycosidase. The resulting  
245 free sugars and deglycosylated GMPs were redissolved in PBS at 10 g L<sup>-1</sup> and diluted to determine  
246 their biological activities (Table 3). The activity of the glycosylated GMPs was consistent with  
247 results shown in Table 2; glycan hydrolysis with sialidase and *O*-glycosidase (Table 3) or with  
248 *O*-glycosidase only (data not shown) eliminated anti-adhesive activity.

## 249 **Discussion**

250 Camel is an important source of milk in many countries including some of the developing countries  
251 where childhood diarrhea caused by ETEC is very common (Jafar, Kamal, Mudgil, Hassan, &  
252 Maqsood, 2018; Jrad et al., 2014). Whey is a byproduct of camel milk cheese production (Jafar et  
253 al., 2018) and is thus an inexpensive source of bioactive compounds including GMP. In the present  
254 study, purification of camel and dromedary GMP was achieved with a protocol that was developed  
255 for purification of bovine GMP (Nakano et al., 2018). The experimental Mw of non-glycosylated  
256 bovine GMP that was observed by LC-MS/MS, 6.787 kDa, matches prior observations (Mollé &  
257 Léonil, 1995, 2005), LC-MS data for the GMP from Bactrian camels is not available. The average  
258 molecular weight (Mw) of glycosylated bovine GMP is 7.5 kDa (Kreuss, Krause, & Kulozik,

259 2008). The SDS-PAGE analysis indicates that the GMP from Bactrian camels and dromedaries  
260 form dimers as was previously shown for bovine and goat GMP as a result of self-assembly (Farías,  
261 Martínez, & Pilosof, 2010; Nakano & Ozimek, 2000; Silva-Hernandez, Nakano, & Ozimek, 2002).  
262 The additional bands present in dromedary GMP and bovine GMP correspond to trimeric and  
263 tetrameric GMP. The observation of multimeric aggregated GMP was reported previously after  
264 separation of bovine GMP, which migrates on SDS-PAGE as a mixture of polymers (Farías et al.,  
265 2010; Mikkelsen et al., 2005; Nakano, Noriaki, & Ozimek, 2007). It was suggested that  
266 hydrophobic interactions stabilize the GMP dimers while electrostatic bonds additionally stabilize  
267 the multimeric aggregates of GMP (Farías et al., 2010; Mikkelsen et al., 2005; Nakano et al., 2007).  
268 The multimeric aggregates of GMP were least abundant in the sample prepared from milk of  
269 Bactrian camels; this was also the only sample that was not pasteurized prior to preparation of the  
270 GMP, indicating that pasteurization contributes to the aggregation of bovine and camel GMP.

271 The monosaccharide composition of bovine GMP matches prior reports on its glycan composition  
272 (Holland, Deeth, & Alewood, 2006; Hua et al., 2011). Bovine GMP is glycosylated with a  
273 disaccharide composed of galactose and N-acetylgalactosamine (GalNAc), which is decorated  
274 with one or two N-acetylneuraminic acid (NeuNAc) moieties. Glycosylation with oligosaccharides  
275 that additionally include fucose and N-acetylglucosamine (GlcNAc) were reported in GMP from  
276 bovine colostrum (O’Riordan, Kane, Joshi, & Hickey, 2014). GalNAc and GlcNAc were detected  
277 as the deacetylated amino sugars galactosamine (GalN) and glucosamine (GlcN). This is the result  
278 of extensive deacetylation during TFA hydrolysis (Dolgopyatova, Novikov, Konovalova, &  
279 Putintsev, 2013; Gizatulina, Chebotok, Novikov, & Konovalova, 2005; Prechtel, Wefers, Jakob, &  
280 Vogel, 2018). Falsification of the results by naturally occurring GalN and GlcN is unlikely because  
281 they are highly reactive in the Maillard reaction (Hrynets, Ndagijimana, & Betti, 2015) and were

282 not identified in glycoproteins in milk (O’Riordan et al., 2014). NeuNAc is also degraded when  
283 high temperatures are applied during acid treatment (Zhu, Chen, Yuan, Wu, & Yao, 2020).  
284 Therefore, the reaction temperature during TFA hydrolysis was reduced to 70 °C which allowed  
285 the quantification of NeuNAc in the different GMPs.

286 The monosaccharide content of GMPs from Bactrian camels and dromedaries was about twice as  
287 high as bovine GMP, corresponding to the higher number of potential glycosylation sites in these  
288 two species (Fig. 3). The difference is more significant for galactose, GalNAc, NeuNAc and  
289 GlcNAc. For instance, the content of GlcNAc in Bactrian camel and dromedary is 6 - 8 fold higher  
290 than in bovine GMP (Table 1). Many of the biological activities of GMP are mediated by the  
291 glycan structure (O’Riordan et al., 2014), therefore, the increased glycan content of GMP from  
292 *Camelus* species may also impact their biological activity.

293 ETEC K88 infect young piglets and calves (Moonens et al., 2015), and K88 fimbriae mediate the  
294 binding of *E. coli* ECL13795 to glycan receptors (Jin & Zhao, 2000). Porcine aminopeptidase N  
295 is a receptor for F4 (K88) fimbriae; in addition, surface glycan oligosaccharides composed of  
296 GalNAc, GlcNAc, GalN, and N-acetylmannosamine were proposed as receptors for ETEC K88  
297 adhesion (Jin & Zhao, 2000; Moonens et al., 2015). GMP from both Bactrian camels and  
298 dromedaries showed potent anti-adhesive activity at concentrations of about 0.25 g L<sup>-1</sup>, which is  
299 about 20-fold lower than the effective concentration of bovine GMP (Hermes et al., 2013; Sun,  
300 Gänzle, & Wu, 2019). This increased activity *in vitro* likely relates to the increased glycosylation  
301 and / or differences in the glycan composition and may also translate to an increased activity *in*  
302 *vivo*. Bovine GMP also reduced the attachment of ETEC K88 *in vivo* (Hermes et al., 2013; Rong  
303 et al., 2015) and improved growth performance of *E. coli* K88-challenged piglets (Hermes et al.,  
304 2013; Rong et al., 2015).

305 This relationship of glycan structure to biological activity was confirmed by comparison of the  
306 activity of glycosylated GMPs to the activity of free oligosaccharides and GMPs after enzymatic  
307 deglycosylation (Table 3). Free oligosaccharides from camel milk were less active than GMP and  
308 deglycosylation of GMP strongly reduced the prevention of ETEC adhesion. The higher activity  
309 of the more densely glycosylated camel GMP, and the strong decrease of activity after  
310 deglycosylation suggests that not only the structure but also the density spacing of glycans on the  
311 peptide backbone are important for anti-adhesive activity. The topological spacing of glycans is  
312 recognized as an important factor affecting the anti-adhesive activity of glycopeptides (Lewallen,  
313 Siler, & Iyer, 2009; Nakajima et al., 2005; Oyelaran & Gildersleeve, 2009; Oyelaran, Li,  
314 Farnsworth, & Gildersleeve, 2009).

315 In conclusion, hemagglutination and ELISA assays indicate that the anti-adhesive activity of GMP  
316 from Bactrian camels and dromedaries was substantially higher than the activity of bovine GMP.  
317 Free oligosaccharides from camel milk that were prepared as a control were also active but at a  
318 higher concentration when compared to GMP. Deglycosylation of GMP suggested that the spatial  
319 arrangement of glycans on the peptide backbone contributes to anti-adhesive activity. The *in vitro*  
320 anti-adhesive activity of bovine GMP was confirmed to also reduce ETEC K88 adhesion *in vivo*  
321 (Hermes et al., 2013). Therefore, it is likely that the *in vitro* activity of GMP from *Camelus* species  
322 (this study) also translates to *in vivo* activity in swine. ETEC that infect humans, however, use  
323 different fimbriae with different binding specificity when compared to porcine ETEC (Eigel et al.,  
324 1984; Nagy & Fekete, 2005), therefore, the use of GMP from camels and dromedaries remains  
325 subject to future investigations.

## 326 **Acknowledgements**

327 We acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC),  
328 Canada Research Chairs (CRC), and Mutah University, Jordan, respectively, for their funding. We  
329 are grateful for Chr. Hansen, Australia for providing the camel chymosin enzyme.

### 330 **References**

331 Ackerman, D. L., Craft, K. M., & Townsend, S. D. (2017). Infant food applications of complex  
332 carbohydrates: structure, synthesis, and function. *Carbohydrate Research*, 437, 16.  
333 <https://doi.org/10.1016/J.CARRES.2016.11.007>

334 Al-Ruwaili, M. A., Khalil, O. M., & Selim, S. A. (2012). Viral and bacterial infections associated  
335 with camel (*Camelus dromedarius*) calf diarrhea in north province, Saudi Arabia. *Saudi*  
336 *Journal of Biological Sciences*, 19(1), 35–41. <https://doi.org/10.1016/J.SJBS.2011.10.001>

337 Bode, L., Contractor, N., Barile, D., Pohl, N., Prudden, A. R., Boons, G.-J., ... Jennewein, S.  
338 (2016). Overcoming the limited availability of human milk oligosaccharides: challenges and  
339 opportunities for research and application. *Nutrition Reviews*, 74(10), 635.  
340 <https://doi.org/10.1093/NUTRIT/NUW025>

341 Chen, X. Y., Woodward, A., Zijlstra, R. T., & Gänzle, M. G. (2014). Exopolysaccharides  
342 synthesized by *Lactobacillus reuteri* protect against enterotoxigenic *Escherichia coli* in  
343 piglets. *Applied and Environmental Microbiology*, 80(18), 5752–5760.  
344 <https://doi.org/10.1128/AEM.01782-14>

345 Docic, M., & Bilkei, G. (2003). Differences in antibiotic resistance in *Escherichia coli*, isolated  
346 from East-European swine herds with or without prophylactic use of antibiotics. *Journal of*  
347 *Veterinary Medicine, Series B*, 50(1), 27–30. [https://doi.org/10.1046/j.1439-](https://doi.org/10.1046/j.1439-0450.2003.00609.x)  
348 [0450.2003.00609.x](https://doi.org/10.1046/j.1439-0450.2003.00609.x)



349 Dolgopyatova, N. V, Novikov, V. Y., Konovalova, I. N., & Putintsev, N. M. (2013). Organic and  
350 petrochemical processes mechanism of acid hydrolysis of N-acetyl-D-glucosamine. *Russian*  
351 *Journal of Applied Chemistry*, 86(7), 1052–1058.  
352 <https://doi.org/10.1134/S1070427213070070>

353 DuPont, H. (1995). Pathogenesis of traveler’s diarrhea. *Chemotherapy*, 41 Suppl 1, 33–39.  
354 <https://doi.org/10.1159/000239395>

355 Eigel, W. N., Butler, J. E., Ernstrom, C. A., Farrell, H. M., Harwalkar, V. R., Jenness, R., &  
356 Whitney, R. M. L. (1984). Nomenclature of proteins of cow’s milk: Fifth revision. *Journal*  
357 *of Dairy Science*, 67(8), 1599–1631. [https://doi.org/10.3168/JDS.S0022-0302\(84\)81485-X](https://doi.org/10.3168/JDS.S0022-0302(84)81485-X)

358 El-Agamy, E. I. (2009). Bioactive components in camel milk. Bioactive components in milk and  
359 dairy products . (pp. 159–192). Wiley-Blackwell.

360 Fariás, M. E., Martinez, M. J., & Pilosof, A. M. R. (2010). Casein glycomacropeptide pH-  
361 dependent self-assembly and cold gelation. *International Dairy Journal*, 20(2), 79–88.  
362 <https://doi.org/10.1016/J.IDAIRYJ.2009.09.002>

363 Fong, B., Ma, K., & McJarrow, P. (2011). Quantification of bovine milk oligosaccharides using  
364 liquid chromatography–selected reaction monitoring–mass spectrometry. *Journal of*  
365 *Agricultural and Food Chemistry*, 59(18), 9788–9795. <https://doi.org/10.1021/JF202035M>

366 Gizatulina, G. A., Chebotok, E. N., Novikov, V. Y., & Konovalova, I. N. (2005). Kinetics of acid  
367 hydrolysis of acetylglucosamine. *Russian Journal of Applied Chemistry*, 78(5), 791–793.  
368 <https://doi.org/10.1007/S11167-005-0393-X>

369 Hermes, R. G., Manzanilla, E. G., Martín-Orúe, S. M., Pérez, J. F., & Klasing, K. C. (2011).  
370 Influence of dietary ingredients on in vitro inflammatory response of intestinal porcine

371 epithelial cells challenged by an enterotoxigenic *Escherichia coli* (K88). *Comparative*  
372 *Immunology, Microbiology and Infectious Diseases*, 34(6), 479–488.  
373 <https://doi.org/10.1016/j.cimid.2011.08.006>

374 Hermes, R. G., Molist, F., Francisco Pérez, J., De Segura, A. G., Ywazaki, M., Davin, R., ...  
375 Martín-Orúe, S. M. (2013). Casein glycomacropeptide in the diet may reduce *Escherichia*  
376 *coli* attachment to the intestinal mucosa and increase the intestinal *lactobacilli* of early  
377 weaned piglets after an enterotoxigenic *E. coli* K88 challenge. *British Journal of Nutrition*,  
378 109(6), 1001–1012. <https://doi.org/10.1017/S0007114512002978>

379 Holland, J. W., Deeth, H. C., & Alewood, P. F. (2006). Resolution and characterisation of multiple  
380 isoforms of bovine  $\kappa$ -casein by 2-DE following a reversible cysteine-tagging enrichment  
381 strategy. *PROTEOMICS*, 6(10), 3087–3095. <https://doi.org/10.1002/PMIC.200500780>

382 Hrynets, Y., Ndagijimana, M., & Betti, M. (2015). Studies on the formation of maillard and  
383 caramelization products from glucosamine incubated at 37 °C. *Journal of Agricultural and*  
384 *Food Chemistry*, 63(27), 6249–6261. <https://doi.org/10.1021/ACS.JAFC.5B02664>

385 Hua, S., Nwosu, C. C., Strum, J. S., Seipert, R. R., An, H. J., Zivkovic, A. M., ... Lebrilla, C. B.  
386 (2011). Site-specific protein glycosylation analysis with glycan isomer differentiation.  
387 *Analytical and Bioanalytical Chemistry* 2011 403:5, 403(5), 1291–1302.  
388 <https://doi.org/10.1007/S00216-011-5109-X>

389 Ishii-Karakasa, I., Iwase, H., Hotta, K., Tanaka, Y., & Omura, S. (1992). Partial purification and  
390 characterization of an endo-alpha-N-acetylgalactosaminidase from the culture medium of  
391 *Streptomyces* sp. OH-11242. *Biochemical Journal*, 288(Pt 2), 482.  
392 <https://doi.org/10.1042/BJ2880475>

393 Jafar, S., Kamal, H., Mudgil, P., Hassan, H. M., & Maqsood, S. (2018). Camel whey protein  
394 hydrolysates displayed enhanced cholesteryl esterase and lipase inhibitory, anti-hypertensive  
395 and anti-haemolytic properties. *LWT*, 98, 212–218.  
396 <https://doi.org/10.1016/J.LWT.2018.08.024>

397 Jin, L. Z., & Zhao, X. (2000). Intestinal receptors for adhesive fimbriae of enterotoxigenic  
398 *Escherichia coli* (ETEC) K88 in swine - a review. *Applied Microbiology and Biotechnology*,  
399 54(3), 311–318. <https://doi.org/10.1007/s002530000404>

400 Jrad, Z., El Hatmi, H., Adt, I., Girardet, J.-M., Cakir-Kiefer, C., Jardin, J., ... Jardin, J. (2014).  
401 Effect of digestive enzymes on antimicrobial, radical scavenging and angiotensin I-  
402 converting enzyme inhibitory activities of camel colostrum and milk proteins. *Dairy Science*  
403 *& Technology*, 94, 205–224. <https://doi.org/10.1007/s13594-013-0154-1i>

404 Krachler, A. M., & Orth, K. (2013). Targeting the bacteria–host interface. *Virulence*, 4(4), 284–  
405 294. <https://doi.org/10.4161/VIRU.24606>

406 Kreuss, M., Krause, I., & Kulozik, U. (2008). Separation of a glycosylated and non-glycosylated  
407 fraction of caseinomacropptide using different anion-exchange stationary phases. *Journal of*  
408 *Chromatography. A*, 1208(1–2), 126–132. <https://doi.org/10.1016/J.CHROMA.2008.08.073>

409 Kulkarni, A. A., Weiss, A. A., & Iyer, S. S. (2010). Glycan-based high-affinity ligands for toxins  
410 and pathogen receptors. *Medicinal Research Reviews*, 30(2), 327–393.  
411 <https://doi.org/10.1002/MED.20196>

412 Lewallen, D., Siler, D., & Iyer, S. (2009). Factors affecting protein-glycan specificity: effect of  
413 spacers and incubation time. *Chembiochem: A European Journal of Chemical Biology*,  
414 10(9), 1486–1489. <https://doi.org/10.1002/CBIC.200900211>

415 Li, E. W. Y., & Mine, Y. (2004). Technical note: comparison of chromatographic profile of  
416 glycomacropeptide from cheese whey isolated using different methods. *Journal of Dairy*  
417 *Science*, 87, 174–177. [https://doi.org/10.3168/jds.S0022-0302\(04\)73155-0](https://doi.org/10.3168/jds.S0022-0302(04)73155-0)

418 Mikkelsen, T. L., Frøkiaer, H., Topp, C., Bonomi, F., Iametti, S., Picariello, G., ... Barkholt, V.  
419 (2005). Caseinomacropeptide self-association is dependent on whether the peptide is free or  
420 restricted in  $\kappa$ -casein. *Journal of Dairy Science*, 88, 4228–4238.  
421 [https://doi.org/10.3168/jds.S0022-0302\(05\)73109-X](https://doi.org/10.3168/jds.S0022-0302(05)73109-X)

422 Mollé, D., & Léonil, J. (1995). Heterogeneity of the bovine  $\kappa$ -casein caseinomacropeptide,  
423 resolved by liquid chromatography on-line with electrospray ionization mass spectrometry.  
424 *Journal of Chromatography A*, 708(2), 223–230. [https://doi.org/10.1016/0021-](https://doi.org/10.1016/0021-9673(95)00386-2)  
425 [9673\(95\)00386-2](https://doi.org/10.1016/0021-9673(95)00386-2)

426 Mollé, D., & Léonil, J. (2005). Quantitative determination of bovine  $\kappa$ -casein macropeptide in  
427 dairy products by Liquid chromatography/Electrospray coupled to mass spectrometry (LC-  
428 ESI/MS) and Liquid chromatography/Electrospray coupled to tandem mass spectrometry  
429 (LC-ESI/MS/MS). *International Dairy Journal*, 15(5), 419–428.  
430 <https://doi.org/10.1016/j.idairyj.2004.08.013>

431 Moonens, K., Van Den Broeck, I., De Kerpel, M., Deboeck, F., Raymaekers, H., Remaut, H., &  
432 De Greve, H. (2015). Structural and functional insight into the carbohydrate receptor binding  
433 of F4 fimbriae-producing enterotoxigenic *Escherichia coli*. *Journal of Biological Chemistry*,  
434 290(13), 8409–8419. <https://doi.org/10.1074/JBC.M114.618595>

435 Nagy, B., & Fekete, P. Z. (2005). Enterotoxigenic *Escherichia coli* in veterinary medicine.  
436 *International Journal of Medical Microbiology*, 295(6–7), 443–454.

437 <https://doi.org/10.1016/J.IJMM.2005.07.003>

438 Nakajima, K., Tamura, N., Kobayashi-Hattori, K., Yoshida, T., Hara-Kudo, Y., Ikedo, M., ...  
439 Hattori, M. (2005). Prevention of intestinal infection by glycomacropeptide. *Bioscience,*  
440 *Biotechnology, and Biochemistry*, 69(12), 2294–2301. <https://doi.org/10.1271/BBB.69.2294>

441 Nakano, T., Noriaki, I., & Ozimek, L. (2007). Detection of sialylated phosphorylated  $\kappa$ -casein  
442 glycomacropeptide electrophoresed on polyacrylamide gels and cellulose acetate strips by the  
443 thiobarbituric acid and malachite green dye reactions. *Journal of Agricultural and Food*  
444 *Chemistry*, 55(7), 2714–2726. <https://doi.org/10.1021/JF062987F>

445 Nakano, T., & Ozimek, L. (2000). Purification of glycomacropeptide from caseinate hydrolysate  
446 by gel chromatography and treatment with acidic solution. *Journal of Food Science*, 65(4),  
447 588–590.

448 Nakano, T., Ozimek, L., & Betti, M. (2018). Separation of bovine  $\kappa$ -casein glycomacropeptide  
449 from sweet whey protein products with undetectable level of phenylalanine by protein  
450 precipitation followed by anion exchange chromatography. *Journal of Dairy Research*, 85(1),  
451 110–113. <https://doi.org/10.1017/S0022029917000838>

452 O’Riordan, N., Kane, M., Joshi, L., & Hickey, R. M. (2014). Structural and functional  
453 characteristics of bovine milk protein glycosylation. *Glycobiology*, 24(3), 220–236.  
454 <https://doi.org/10.1093/GLYCOB/CWT162>

455 Oyelaran, O., & Gildersleeve, J. C. (2009). Glycan arrays: recent advances and future challenges.  
456 *Current Opinion in Chemical Biology*, 13(4), 406–413.  
457 <https://doi.org/10.1016/J.CBPA.2009.06.021>

458 Oyelaran, O., Li, Q., Farnsworth, D., & Gildersleeve, J. C. (2009). Microarrays with varying

459 carbohydrate density reveal distinct subpopulations of serum antibodies. *Journal of Proteome*  
460 *Research*, 8(7), 3529–3538. <https://doi.org/10.1021/PR9002245>

461 Prechtel, R. M., Wefers, D., Jakob, F., & Vogel, R. F. (2018). Structural characterization of the  
462 surface-associated heteropolysaccharide of *Lactobacillus plantarum* TMW 1.1478 and  
463 genetic analysis of its putative biosynthesis cluster. *Carbohydrate Polymers*, 202, 236–245.  
464 <https://doi.org/10.1016/J.CARBPOL.2018.08.115>

465 Qadri, F., Svennerholm, A.-M., Faruque, A. S. G., & Sack, R. B. (2005). Enterotoxigenic  
466 *Escherichia coli* in developing countries: epidemiology, microbiology, clinical features,  
467 treatment, and prevention. *CLINICAL MICROBIOLOGY REVIEWS*, 18(3), 465–483.  
468 <https://doi.org/10.1128/CMR.18.3.465-483.2005>

469 Rong, Y., Lu, Z., Zhang, H., Zhang, L., Song, D., & Wang, Y. (2015). Effects of casein  
470 glycomacropeptide supplementation on growth performance, intestinal morphology,  
471 intestinal barrier permeability and inflammatory responses in *Escherichia coli* K88  
472 challenged piglets. *Animal Nutrition*, 1(2), 54–59.  
473 <https://doi.org/10.1016/j.aninu.2015.05.006>

474 Shoaf-Sweeney, K. D., & Hutkins, R. W. (2008). Chapter 2 Adherence, anti-adherence, and  
475 oligosaccharides: preventing pathogens from sticking to the host. In *Advances in Food and*  
476 *Nutrition Research* (Vol. 55, pp. 101–161). Academic Press. [https://doi.org/10.1016/S1043-](https://doi.org/10.1016/S1043-4526(08)00402-6)  
477 [4526\(08\)00402-6](https://doi.org/10.1016/S1043-4526(08)00402-6)

478 Silva-Hernandez, E., Nakano, T., & Ozimek, L. (2002). Isolation and analysis of kappa-casein  
479 glycomacropeptide from goat sweet whey. *Journal of Agricultural and Food Chemistry*,  
480 50(7), 2034–2038.

481 Sun, X., Gänzle, M., & Wu, J. (2017). Identification and characterization of glycopeptides from  
482 egg protein ovomucin with anti-agglutinating activity against porcine K88 enterotoxigenic  
483 *Escherichia coli* strains. *Journal of Agricultural and Food Chemistry*, 65(4), 777–783.  
484 <https://doi.org/10.1021/acs.jafc.6b04299>

485 Sun, X., Gänzle, M., & Wu, J. (2019). Glycopeptides from egg white ovomucin inhibit K88 ac  
486 enterotoxigenic *Escherichia coli* adhesion to porcine small intestinal epithelial cell-line.  
487 *Journal of Functional Foods*, 54(January), 320–328.  
488 <https://doi.org/10.1016/j.jff.2019.01.033>

489 Wang, Y., Gänzle, M., & Schwab, C. (2010). Exopolysaccharide synthesized by *Lactobacillus*  
490 *reuteri* decreases the ability of enterotoxigenic *Escherichia coli* to bind to porcine  
491 erythrocytes. *Appl Environ Microbiol*, 76(14), 4863–4866.  
492 <https://doi.org/10.1128/aem.03137-09>

493 Warren, L. (1959). The thiobarbituric acid assay of sialic acids. *The Journal of Biological*  
494 *Chemistry*, 234(8), 1971–1975. [https://doi.org/10.1016/S0021-9258\(18\)69851-5](https://doi.org/10.1016/S0021-9258(18)69851-5)

495 Yan, Y. L., Hu, Y., Simpson, D. J., & Gänzle, M. G. (2017). Enzymatic synthesis and purification  
496 of galactosylated chitosan oligosaccharides reducing adhesion of enterotoxigenic *Escherichia*  
497 *coli* K88. *Journal of Agricultural and Food Chemistry*, 65(25), 5142–5150.  
498 <https://doi.org/10.1021/acs.jafc.7b01741>

499 Zhu, W., Chen, X., Yuan, L., Wu, J., & Yao, J. (2020). Degradation kinetics and shelf life of N-  
500 acetylneuraminic acid at different pH values. *Molecules (Basel, Switzerland)*, 25(21), 5141.  
501 <https://doi.org/10.3390/MOLECULES25215141>

502

503

504 **Figure legends**

505 **Figure 1.** Flow diagram for the purification of the glycomacropeptide (GMP) from camel milk

506 **Figure 2.** Separation of the GMP from milk of Bactrian camels (**Panel A**) and dromedaries (**Panel**  
507 **B**) on a diethylaminoethyl (DEAE)- Sephadex A-25 column. Sialylated oligosaccharides were  
508 eluted with 0.5 M NaCl and detected at 549 nm after derivatization. Camel milk oligosaccharides  
509 were prepared as negative control from milk that was not treated with rennet.

510 **Figure 3.** Amino acid sequence of the glycomacropeptide (C-terminus of  $\kappa$ -casein) from Bactrian  
511 camel (L0P304), dromedary (P79139), and cows (P02668). Green colored amino acids indicate  
512 the glycomacropeptide (GMP); bold residues indicate potential sites for glycosylation or  
513 phosphorylation. Bold blue-colored letters correspond to amino acids that were shown to be  
514 glycosylated in variant A of bovine GMP; red-colored letters correspond to amino acids that were  
515 shown to be phosphorylated in variant A of bovine GMP.(Eigel et al., 1984) The red arrow  
516 indicates the cleave sites of chymosin.

517 **Figure 4.** Separation of purified GMP from Bactrian camel and dromedary, and of commercial  
518 bovine GMP by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).

519 **Figure 5.** Quantification of *E. coli* K88 ECL13795 binding to porcine erythrocytes with ELISA  
520 targeting K88 antibodies. ETEC were incubated with erythrocytes without addition of GMP (no  
521 GMP control) or with addition of different concentrations of GMPs. Lactose, bovine serum  
522 albumin, and acidic oligosaccharides from milk from Bactrian camels served as controls. Based  
523 on the yield of GMP and acidic oligosaccharides from the milk of Bactrian camels, 50 and 5 mg /  
524 L, respectively, the GMP preparation from Bactrian camels included about 10% of acidic  
525 oligosaccharides in addition to the GMP. Values obtained with different compounds or



526 preparations at the same concentration differ significantly ( $P < 0.05$ ) if they do not share a common  
527 letter. Results are reported as means  $\pm$  standard deviation of three independent assays.

528

**Table 1.** Composition of monosaccharides after hydrolysis of bovine, Bactrian camel, or dromedary GMP with 2 M TFA. The error was calculated from the Residual Standard Error of the linear or linear quadratic regression of the standard curves.

<b>amount mg sugar g<sup>-1</sup> GMP (molar ratio)<sup>a)</sup></b>	<b>Bovine</b>	<b>Bactrian camel</b>	<b>Dromedary</b>
Gal	22.13 ± 0.35 (1)	58.63 ± 0.76 (1)	53.15 ± 0.23 (1) (0.295)
GalN	20.54 ± 0.18 (1)	38.53 ± 0.17 (0.7)	33.23 ± 0.23 (0.6)
NeuNAc <sup>b)</sup>	39.06 ± 0.27 (1)	52.98 ± 0.25 (0.5)	64.68 ± 0.28 (0.7)
GlcN	1.24 ± 0.16 (0.1)	19.75 ± 0.22 (0.3)	15.10 ± 0.05 (0.3)
Glc	1.48 ± 0.35 (0.1)	6.81 ± 0.31 (0.1)	12.03 ± 0.37 (0.2)
GalA	n.d. <sup>c)</sup>	0.73 ± 0.16 (<0.1)	n.d.
Fuc	n.d.	0.43 ± 0.10 (<0.1)	0.60 ± 0.05 (<0.1)
GlcA	n.d.	traces <sup>d)</sup>	n.d.
GlcNAc, GalNAc and Neu5GC	n.d.	n.d.	n.d.
Sum of all sugars	84.4	178.0	178.2

<sup>a)</sup> The molar ratio was calculated relative to galactose and rounded to one significant digit.

Gal, galactose; GalN, galactosamine; NeuNAc, N-acetylneuraminic acid; GlcN, glucosamine, Glc, glucose, GalA, galacturonic acid; Fuc, fucose, GlcA, glucosamine, GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; Neu5GC, N-glycoylneuraminic acid.

<sup>b)</sup> The NeuNAc concentration was determined after hydrolysis at 70 °C.

<sup>c)</sup> n.d., not detected.

<sup>d)</sup> Concentration between limit of detection and limit of quantitation.



**Table 2.** Inhibition of erythrocyte agglutination by ETEC K88 strain with Bactrian camel GMP, dromedary camel GMP, bovine GMP, oligosaccharides from camel acidic whey, bovine serum albumin (BSA), and lactose. Data for bovine and camel GMPs and acidic oligosaccharides are shown as means  $\pm$  standard deviation of three independent preparations from dry milk. Values obtained with different compounds or preparations at the same concentration differ significantly ( $P < 0.05$ ) if they do not share common letter.

sample	minimum concentration for erythrocyte agglutination with ETEC (g L <sup>-1</sup> )
Bactrian camel GMP <sup>A</sup>	0.24 <sup>b</sup> $\pm$ 0.02
Dromedary camel GMP	0.28 <sup>b</sup> $\pm$ 0.03
Bovine GMP	5.52 <sup>a</sup> $\pm$ 1.06
Oligosaccharides from milk of Bactrian camel	0.87 <sup>b</sup> $\pm$ 0.15
Lactose	> 10
BSA	> 10

<sup>A</sup> The preparations of camel GMP included about 10 % acidic oligosaccharides

**Table 3.** Inhibition of erythrocyte agglutination by ETEC K88 strain with Bactrian camel GMP, dromedary camel GMP, and bovine GMP before and after enzymatic deglycosylation with sialidase and O-glycosidase. Data for camel GMPs and bovine GMP are shown as means  $\pm$  standard deviation of three independent assays for the same preparations. Values obtained with different compounds or preparations differ significantly ( $P<0.05$ ) if they do not share a common superscript.

sample	minimum concentration for erythrocyte agglutination with ETEC (g L <sup>-1</sup> )	
	Before deglycosylation	After deglycosylation
Bactrian camel GMP	0.25 <sup>b</sup> $\pm$ 0.00	> 10
Dromedary camel GMP	0.25 <sup>b</sup> $\pm$ 0.00	> 10
Bovine GMP	5.00 <sup>a</sup> $\pm$ 0.00	> 10
Control (just enzyme/ no GMP)	> 10	> 10




Figure 1:




Figure 2.

**Bactrian:**    SFIAI<sup>100</sup> PPKKTQDKTV NPAINTVATV EPPVIPTAEP AVNTVVIAEA **SSEFITTTSTP**<sup>150</sup>  
                   ↓  
                   ↓  
**Dromedary:** SFIAI<sup>100</sup> PPKKTQDKTV NPAINTVATV EPPVIPTAEP AVNTVVIAEA **SSEFITTTSTP**<sup>150</sup>  
                   ↓  
**Bovine:**     SFMAI<sup>108</sup> PPKKNQDKTE IPTINTIASG EPTSTPTTEA VESTVALED **S**PEVIESPPE<sup>158</sup>

**Bactrian:**    ETTTVQITST EI<sup>162</sup>  
**Dromedary:** ETTTVQITST EI<sub>162</sub>  
**Bovine:**     EVIESPPEIN TVQVTSTAV<sup>169</sup>

Figure 3.






Figure 4.




Figure 5.

Graphic abstract: Anti-adhesion activity of different GMP against ETEC

Table of Content Graph

